DOXIMITY INC-CLASS A (DOCS) Stock Fundamental Analysis
USA - New York Stock Exchange - NYSE:DOCS - US26622P1075 - Common Stock
51.31 USD
-0.22 (-0.43%)
51.3 USD
-0.01 (-0.02%)
Overall DOCS gets a fundamental rating of 7 out of 10. We evaluated DOCS against 35 industry peers in the Health Care Technology industry. DOCS scores excellent points on both the profitability and health parts. This is a solid base for a good stock. DOCS is growing strongly while it is still valued neutral. This is a good combination! These ratings could make DOCS a good candidate for growth and quality investing.
1. Profitability
1.1 Basic Checks
In the past year DOCS was profitable.
In the past year DOCS had a positive cash flow from operations.
Each year in the past 5 years DOCS has been profitable.
DOCS had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
DOCS has a better Return On Assets (20.13%) than 100.00% of its industry peers.
Looking at the Return On Equity, with a value of 23.10%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
DOCS's Return On Invested Capital of 18.16% is amongst the best of the industry. DOCS outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for DOCS is significantly above the industry average of 6.67%.
The last Return On Invested Capital (18.16%) for DOCS is above the 3 year average (14.17%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROIC | 18.16% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
1.3 Margins
Looking at the Profit Margin, with a value of 40.72%, DOCS belongs to the top of the industry, outperforming 100.00% of the companies in the same industry.
In the last couple of years the Profit Margin of DOCS has grown nicely.
DOCS has a Operating Margin of 39.72%. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS's Operating Margin has improved in the last couple of years.
DOCS has a better Gross Margin (90.20%) than 97.14% of its industry peers.
In the last couple of years the Gross Margin of DOCS has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% |
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is well above the Cost of Capital (WACC), so DOCS is creating value.
The number of shares outstanding for DOCS has been increased compared to 1 year ago.
Compared to 5 years ago, DOCS has more shares outstanding
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 38.10 indicates that DOCS is not in any danger for bankruptcy at the moment.
DOCS has a Altman-Z score of 38.10. This is amongst the best in the industry. DOCS outperforms 100.00% of its industry peers.
DOCS has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 38.1 |
ROIC/WACC1.86
WACC9.77%
2.3 Liquidity
A Current Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
DOCS has a Current ratio of 7.79. This is amongst the best in the industry. DOCS outperforms 94.29% of its industry peers.
A Quick Ratio of 7.79 indicates that DOCS has no problem at all paying its short term obligations.
DOCS's Quick ratio of 7.79 is amongst the best of the industry. DOCS outperforms 94.29% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 |
3. Growth
3.1 Past
DOCS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 46.43%, which is quite impressive.
The Earnings Per Share has been growing by 79.21% on average over the past years. This is a very strong growth
The Revenue has grown by 20.21% in the past year. This is a very strong growth!
Measured over the past years, DOCS shows a very strong growth in Revenue. The Revenue has been growing by 37.42% on average per year.
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
3.2 Future
Based on estimates for the next years, DOCS will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.75% on average per year.
The Revenue is expected to grow by 11.49% on average over the next years. This is quite good.
EPS Next Y9.97%
EPS Next 2Y10.23%
EPS Next 3Y12.03%
EPS Next 5Y14.75%
Revenue Next Year12.23%
Revenue Next 2Y11.74%
Revenue Next 3Y11.97%
Revenue Next 5Y11.49%
3.3 Evolution
The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
DOCS is valuated quite expensively with a Price/Earnings ratio of 31.29.
Based on the Price/Earnings ratio, DOCS is valued a bit cheaper than 77.14% of the companies in the same industry.
When comparing the Price/Earnings ratio of DOCS to the average of the S&P500 Index (26.41), we can say DOCS is valued inline with the index average.
With a Price/Forward Earnings ratio of 29.95, DOCS can be considered very expensive at the moment.
65.71% of the companies in the same industry are more expensive than DOCS, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 35.40. DOCS is around the same levels.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.29 | ||
| Fwd PE | 29.95 |
4.2 Price Multiples
DOCS's Enterprise Value to EBITDA is on the same level as the industry average.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of DOCS indicates a somewhat cheap valuation: DOCS is cheaper than 65.71% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 30.95 | ||
| EV/EBITDA | 31.22 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates DOCS does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of DOCS may justify a higher PE ratio.
DOCS's earnings are expected to grow with 12.03% in the coming years. This may justify a more expensive valuation.
PEG (NY)3.14
PEG (5Y)0.39
EPS Next 2Y10.23%
EPS Next 3Y12.03%
5. Dividend
5.1 Amount
DOCS does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
51.31
-0.22 (-0.43%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners90.54%
Inst Owner Change-0.05%
Ins Owners1.94%
Ins Owner Change0.19%
Market Cap9.66B
Revenue(TTM)621.33M
Net Income(TTM)253.03M
Analysts76.92
Price Target71.12 (38.61%)
Short Float %3.85%
Short Ratio2.96
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.98%
Min EPS beat(2)16.41%
Max EPS beat(2)17.55%
EPS beat(4)4
Avg EPS beat(4)25.31%
Min EPS beat(4)16.41%
Max EPS beat(4)36.67%
EPS beat(8)8
Avg EPS beat(8)23.42%
EPS beat(12)12
Avg EPS beat(12)22.47%
EPS beat(16)16
Avg EPS beat(16)28.98%
Revenue beat(2)2
Avg Revenue beat(2)3.67%
Min Revenue beat(2)2.52%
Max Revenue beat(2)4.82%
Revenue beat(4)4
Avg Revenue beat(4)4.22%
Min Revenue beat(4)1.38%
Max Revenue beat(4)8.16%
Revenue beat(8)7
Avg Revenue beat(8)3.68%
Revenue beat(12)9
Avg Revenue beat(12)2.53%
Revenue beat(16)12
Avg Revenue beat(16)2.69%
PT rev (1m)0.24%
PT rev (3m)2.03%
EPS NQ rev (1m)-0.69%
EPS NQ rev (3m)0.14%
EPS NY rev (1m)0.27%
EPS NY rev (3m)0.04%
Revenue NQ rev (1m)0.8%
Revenue NQ rev (3m)0.84%
Revenue NY rev (1m)0.24%
Revenue NY rev (3m)0.18%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 31.29 | ||
| Fwd PE | 29.95 | ||
| P/S | 15.55 | ||
| P/FCF | 30.95 | ||
| P/OCF | 30.21 | ||
| P/B | 8.82 | ||
| P/tB | 9.94 | ||
| EV/EBITDA | 31.22 |
EPS(TTM)1.64
EY3.2%
EPS(NY)1.71
Fwd EY3.34%
FCF(TTM)1.66
FCFY3.23%
OCF(TTM)1.7
OCFY3.31%
SpS3.3
BVpS5.82
TBVpS5.16
PEG (NY)3.14
PEG (5Y)0.39
Graham Number14.65
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 20.13% | ||
| ROE | 23.1% | ||
| ROCE | 22.1% | ||
| ROIC | 18.16% | ||
| ROICexc | 85.05% | ||
| ROICexgc | 177.37% | ||
| OM | 39.72% | ||
| PM (TTM) | 40.72% | ||
| GM | 90.2% | ||
| FCFM | 50.23% |
ROA(3y)13.75%
ROA(5y)12.65%
ROE(3y)16.22%
ROE(5y)15.68%
ROIC(3y)14.17%
ROIC(5y)16.48%
ROICexc(3y)82.49%
ROICexc(5y)193.92%
ROICexgc(3y)186.25%
ROICexgc(5y)N/A
ROCE(3y)17.25%
ROCE(5y)20.05%
ROICexgc growth 3Y3.35%
ROICexgc growth 5YN/A
ROICexc growth 3Y-4.75%
ROICexc growth 5YN/A
OM growth 3Y6.88%
OM growth 5Y16.16%
PM growth 3Y0.28%
PM growth 5Y33.35%
GM growth 3Y0.66%
GM growth 5Y0.68%
F-Score9
Asset Turnover0.49
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 64.81% | ||
| Cap/Sales | 1.23% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 123.66% | ||
| Profit Quality | 123.35% | ||
| Current Ratio | 7.79 | ||
| Quick Ratio | 7.79 | ||
| Altman-Z | 38.1 |
F-Score9
WACC9.77%
ROIC/WACC1.86
Cap/Depr(3y)59.31%
Cap/Depr(5y)83.25%
Cap/Sales(3y)1.28%
Cap/Sales(5y)1.55%
Profit Quality(3y)131.35%
Profit Quality(5y)169.54%
High Growth Momentum
Growth
EPS 1Y (TTM)46.43%
EPS 3Y20.79%
EPS 5Y79.21%
EPS Q2Q%50%
EPS Next Y9.97%
EPS Next 2Y10.23%
EPS Next 3Y12.03%
EPS Next 5Y14.75%
Revenue 1Y (TTM)20.21%
Revenue growth 3Y18.42%
Revenue growth 5Y37.42%
Sales Q2Q%23.16%
Revenue Next Year12.23%
Revenue Next 2Y11.74%
Revenue Next 3Y11.97%
Revenue Next 5Y11.49%
EBIT growth 1Y22.24%
EBIT growth 3Y26.56%
EBIT growth 5Y59.63%
EBIT Next Year15.19%
EBIT Next 3Y13.86%
EBIT Next 5Y14.23%
FCF growth 1Y94.7%
FCF growth 3Y30.18%
FCF growth 5Y64.72%
OCF growth 1Y93.3%
OCF growth 3Y29.24%
OCF growth 5Y59.83%
DOXIMITY INC-CLASS A / DOCS FAQ
What is the fundamental rating for DOCS stock?
ChartMill assigns a fundamental rating of 7 / 10 to DOCS.
Can you provide the valuation status for DOXIMITY INC-CLASS A?
ChartMill assigns a valuation rating of 4 / 10 to DOXIMITY INC-CLASS A (DOCS). This can be considered as Fairly Valued.
How profitable is DOXIMITY INC-CLASS A (DOCS) stock?
DOXIMITY INC-CLASS A (DOCS) has a profitability rating of 9 / 10.
What is the earnings growth outlook for DOXIMITY INC-CLASS A?
The Earnings per Share (EPS) of DOXIMITY INC-CLASS A (DOCS) is expected to grow by 9.97% in the next year.